A Phase 2 Study of Duvelisib in Subjects With Refractory Indolent Non-Hodgkin Lymphoma (DYNAMO)

Trial Profile

A Phase 2 Study of Duvelisib in Subjects With Refractory Indolent Non-Hodgkin Lymphoma (DYNAMO)

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 06 Sep 2017

At a glance

  • Drugs Duvelisib (Primary)
  • Indications Chronic lymphocytic leukaemia; Follicular lymphoma; MALT lymphoma; Non-Hodgkin's lymphoma
  • Focus Registrational; Therapeutic Use
  • Acronyms DYNAMO
  • Sponsors Infinity Pharmaceuticals; Verastem
  • Most Recent Events

    • 06 Sep 2017 According to a Verastem Media Release, the company plans to share clinical data from DUO study with U.S. Food and Drug Administration (FDA) for filing a New Drug Application (NDA) with the FDA during the first half of 2018. The duvelisib NDA submission will be supported by favorable results from both DUO and DYNAMO studies.
    • 08 Aug 2017 According to a Verastem media release, results from this trial have been presented at the 14th International Conference on Malignant Lymphoma (ICML).
    • 25 Jun 2017 Results presented at the 22nd Congress of the European Haematology Association
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top